We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Special Report

In vitro human bone marrow analog: clinical potential

    Joan E Nichols

    † Author for correspondence

    Laboratory of Regenerative & Nano-Medicine, Departments of Internal Medicine & Anesthesiology, University of Texas Medical Branch at Galveston, Galveston, TX 77555-0435, USA.

    Search for more papers by this author

    Email the corresponding author at jnichols@utmb.edu

    ,
    Jean Niles

    Search for more papers by this author

    ,
    Shannon Walls

    Search for more papers by this author

    &
    Joaquin Cortiella

    Search for more papers by this author

    Published Online:8 Mar 2010https://doi.org/10.2217/rme.10.7

    Abstract

    Bone marrow is the primary site of hematopoiesis in adult humans. Bone marrow can be cultured in vitro but few simple culture systems fully support hematopoiesis beyond a few months. Human bone marrow analogs are long-term in vitro cultures of marrow stromal and hematopoietic stem cells that can be used to produce cells and products normally harvested from human donors. Bone marrow analog systems should exhibit confluence of the stromal cell populations, persistence of hematopoietic progenitor cells, presence of active regions of hematopoiesis and capacity to produce mature cell types for extended periods of time. Although we are still years away from realizing clinical application of products formed by artificial bone marrow analogs, the process of transitioning this research tool from bench to bedside should be fairly straightforward. The most obvious application of artificial marrow would be for production of autologous hematopoietic CD34+ stem cells as a stem cell therapy for individuals experiencing bone marrow failure due to disease or injury. Another logical application is for ‘blood farming’, a process for large-scale in vitro production of red blood cells, white blood cells or platelets, for transfusion or treatment. Other possibilities include production of nonhematopoietic stem cells such as osteogenic stromal cells, osteoblasts and rare pluripotent stem cells. Bone marrow analogs also have great potential as ex vivo human test systems and could play a critical role in drug discovery, drug development and toxicity testing in the future.

    Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

    Bibliography

    • 1  Dexter TM, Allen TD, Lajtha LG: Conditions controlling the proliferation of haemopoietic stem cells In vitro. J. Cell Physiol.91(3),335–344 (1977).
      Medline CASGoogle Scholar
    • 2  Dexter TM, Wright EG, Krizsa F, Lajtha LG: Regulation of haemopoietic stem cell proliferation in long term bone marrow cultures. Biomedicine27(9–10),344–349 (1977).▪▪ Among the first publications to describe methods for long-term bone marrow culture.
      Medline CASGoogle Scholar
    • 3  Palsson BO, Paek SH, Schwartz RM et al.: Expansion of human bone marrow progenitor cells in a high cell density continuous perfusion system. Biotechnology (NY)11,368–372 (1993).
      Medline CASGoogle Scholar
    • 4  Gartner S, Kaplan HS: Long-term culture of human bone marrow cells. Proc. Natl Acad. Sci. USA77,4756–4759 (1980).
      Medline CASGoogle Scholar
    • 5  Engelhardt M, Douville J, Behringer D et al.: Hematopoietic recovery of ex vivo perfusion culture expanded bone marrow and unexpanded peripheral blood progenitors after myeloablative chemotherapy. Bone Marrow Transplant27,249–259 (2001).
      Medline CASGoogle Scholar
    • 6  Stiff P, Chen B, Franklin W et al.: Autologous transplantation of ex vivo expanded bone marrow cells grown from small aliquots after high-dose chemotherapy for breast cancer. Blood95,2169–2174 (2000).
      Medline CASGoogle Scholar
    • 7  Materna T, Rolf HJ, Napp J et al.: In vitro characterization of three-dimensional scaffolds seeded with human bone marrow stromal cells for tissue engineered growth of bone: mission impossible? A methodological approach. Clin. Oral. Implants Res.19,379–386 (2008).
      MedlineGoogle Scholar
    • 8  Emerson SG, Palsson BO, Clarke MF.: The construction of high efficiency human bone marrow tissue ex vivo. J. Cell Biochem.45,268–272 (1991).
      Medline CASGoogle Scholar
    • 9  Nichols JE, Cortiella J, Lee J et al.: In vitro analog of human bone marrow from 3D scaffolds with biomimetic inverted colloidal crystal geometry. Biomaterials30,1071–1079 (2009).▪▪ First article to compare 2D with 3D culture of human bone marrow that demonstrates maintenance of CD34+ hematopoietic stem cells and production of mature cells. It is also the first article to show the design of a specialized inverted colloidal crystal hydrogel matrix for bone marrow cultivation.
      Medline CASGoogle Scholar
    • 10  Okumoto K, Saito T, Hattori E et al.: Differentiation of rat bone marrow cells cultured on artificial basement membrane containing extracellular matrix into a liver cell lineage. J. Hepatol.43,110–116 (2005).
      Medline CASGoogle Scholar
    • 11  Cheung JO, Casals-Pascual C, Roberts DJ, Watt SM: A small-scale serum-free liquid cell culture model of erythropoiesis to assess the effects of exogenous factors. J. Immunol. Methods319,104–117 (2007).
      Medline CASGoogle Scholar
    • 12  Kasai M, Kiyama Y, Kawamura A: Application of peripheral blood stem cells (PBSC) mobilized by recombinant human granulocyte colony stimulating factor for allogeneic PBSC transplantation and the comparison of allogeneic PBSC transplantation and bone marrow transplantation. Transfus. Apher. Sci.26,121–127 (2002).
      MedlineGoogle Scholar
    • 13  Brugger W, Scheding S, Ziegler B, Buhring HJ, Kanz L: Ex vivo manipulation of hematopoietic stem and progenitor cells. Semin. Hematol.37,42–49 (2000).
      Medline CASGoogle Scholar
    • 14  Varas F, Grande T, Ramirez A, Bueren JA: Implantation of bone marrow beneath the kidney capsule results in transfer not only of functional stroma but also of hematopoietic repopulating cells. Blood96,2307–2309 (2000).
      Medline CASGoogle Scholar
    • 15  Banfi A, Muraglia A, Dozin B et al.: Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: implications for their use in cell therapy. Exp. Hematol.28,707–715 (2000).
      Medline CASGoogle Scholar
    • 16  Mendes SC, Tibbe JM, Veenhof M et al.: Bone tissue-engineered implants using human bone marrow stromal cells: effect of culture conditions and donor age. Tissue Eng.8,911–920 (2002).
      Medline CASGoogle Scholar
    • 17  Javazon EH, Beggs KJ, Flake AW: Mesenchymal stem cells: paradoxes of passaging. Exp. Hematol.32,414–425 (2004).
      Medline CASGoogle Scholar
    • 18  Bianchi G, Banfi A, Mastrogiacomo M et al.: ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2. Exp. Cell Res.287,98–105 (2003).
      Medline CASGoogle Scholar
    • 19  Abbott A: Cell culture: biology’s new dimension. Nature424,870–872 (2003).
      Medline CASGoogle Scholar
    • 20  Jacks T, Weinberg RA: Taking the study of cancer cell survival to a new dimension. Cell111,923–925 (2002).
      Medline CASGoogle Scholar
    • 21  Bancroft GN, Sikavitsas VI, van den DJ et al.: Fluid flow increases mineralized matrix deposition in 3D perfusion culture of marrow stromal osteoblasts in a dose-dependent manner. Proc. Natl Acad. Sci. USA99,12600–12605 (2002).
      Medline CASGoogle Scholar
    • 22  Wendt D, Marsano A, Jakob M et al.: Oscillating perfusion of cell suspensions through three-dimensional scaffolds enhances cell seeding efficiency and uniformity. Biotechnol. Bioeng.84,205–214 (2003).
      Medline CASGoogle Scholar
    • 23  Branccini A, Wendt D, Jaquiery C et al.: Three dimensional perfusion culture of human bone marrow cells and generation of osteoinductive grafts. Stem Cells23,1066–1072 (2005).
      MedlineGoogle Scholar
    • 24  Busch MP, Kleinman SH, Nemo GJ: Current and emerging infectious risks of blood transfusions. JAMA289,959–962 (2003).
      MedlineGoogle Scholar
    • 25  Allain JP, Stramer SL, Carneiro-Proietti AB et al.: Transfusion-transmitted infectious diseases. Biologicals37,71–77 (2009).
      MedlineGoogle Scholar
    • 26  Boehm D, Murphy WG, Al-Rubeai M: The potential of human peripheral blood derived CD34+ cells for ex vivo red blood cell production. J. Biotechnol.144(2),127–134 (2009).
      Medline CASGoogle Scholar
    • 27  Mantalaris A, Keng P, Bourne P, Chang AY, Wu JH: Engineering a human bone marrow model: a case study on ex vivo erythropoiesis. Biotechnol. Prog.14,126–133 (1998).
      Medline CASGoogle Scholar
    • 28  Giarratana MC, Kobari L, Lapillonne H et al.: ex vivo generation of fully mature human red blood cells from hematopoietic stem cells. Nat. Biotechnol.23,69–74 (2005).
      Medline CASGoogle Scholar
    • 29  Douay L, Giarratana MC: In vitro generation of mature and functional human red blood cells: a model with multidisciplinary perspectives. Bull. Acad. Natl Med.189,903–913; discussion 914–915 (2005).
      Medline CASGoogle Scholar
    • 30  Douay L, Giarratana MC: ex vivo generation of human red blood cells: a new advance in stem cell engineering. Methods. Mol. Biol.482,127–140 (2009).
      Medline CASGoogle Scholar
    • 31  Boyer L, Robert A, Proulx C, Pineault N: Increased production of megakaryocytes near purity from cord blood CD34+ cells using a short two-phase culture system. J. Immunol. Methods332,82–91 (2008).
      Medline CASGoogle Scholar
    • 32  Bruno S, Gunetti M, Gammaitoni L et al.: Fast but durable megakaryocyte repopulation and platelet production in NOD/SCID mice transplanted with ex vivo expanded human cord blood CD34+ cells. Stem Cells22,135–143 (2004).
      MedlineGoogle Scholar
    • 33  Cortin V, Pineault N, Garnier A: ex vivo megakaryocyte expansion and platelet production from human cord blood stem cells. Methods Mol. Biol.482,109–126 (2009).
      Medline CASGoogle Scholar
    • 34  Proulx C, Boyer L, Hurnanen DR, Lemieux R: Preferential ex vivo expansion of megakaryocytes from human cord blood CD34+-enriched cells in the presence of thrombopoietin and limiting amounts of stem cell factor and Flt-3 ligand. J. Hematother. Stem Cell Res.12,179–188 (2003).
      Medline CASGoogle Scholar
    • 35  Woo SY, Kie JH, Ryu KH et al.: Megakaryothrombopoiesis during ex vivo expansion of human cord blood CD34+ cells using thrombopoietin. Scand. J. Immunol.55,88–95 (2002).
      Medline CASGoogle Scholar
    • 36  Robertson P, Scadden DT: Differentiation and characterization of T cells. Curr. Protoc. Immunol. Chapter 22, Unit 22F 8 (2005).
      MedlineGoogle Scholar
    • 37  Ramsdell F, Zuniga-Pflucker JC, Takahama Y: In vitro systems for the study of T cell development: fetal thymus organ culture and OP9-DL1 cell coculture. Curr. Protoc. Immunol. Chapter 3, Unit 3, 18 (2006).
      MedlineGoogle Scholar
    • 38  Hare KJ, Jenkinson EJ, Anderson G: In vitro models of T cell development. Semin. Immunol.11,3–12 (1999).
      Medline CASGoogle Scholar
    • 39  Barker J, Verfaillie CM: A novel In vitro model of early human adult B lymphopoiesis that allows proliferation of pro-B cells and differentiation to mature B lymphocytes. Leukemia14,1614–1620 (2000).
      Medline CASGoogle Scholar
    • 40  Fluckiger AC, Sanz E, Garcia-Lloret M et al.: In vitro reconstitution of human B-cell ontogeny: from CD34+ multipotent progenitors to Ig-secreting cells. Blood92,4509–4520 (1998).
      Medline CASGoogle Scholar
    • 41  DeLuca D, Basye JL, Schumacher MJ, Lebsack, TW: Production of human B cells from CD34+CD38- T- B- progenitors in organ culture by sequential cytokine stimulation. Dev. Comp. Immunol.30,1084–1098 (2006).
      Medline CASGoogle Scholar
    • 42  Taguchi T, Takenouchi H, Shiozawa Y et al.: Interleukin-7 contributes to human pro-B-cell development in a mouse stromal cell-dependent culture system. Exp. Hematol.35,1398–1407 (2007).
      Medline CASGoogle Scholar
    • 43  Ichii M, Oritani K, Yokota T et al.: Regulation of human B lymphopoiesis by the transforming growth factor-β superfamily in a newly established coculture system using human mesenchymal stem cells as a supportive microenvironment. Exp. Hematol.36,587–597 (2008).
      Medline CASGoogle Scholar
    • 44  Sullenbarger B, Bahng JH, Gruner R, Kotov N, Lasky LC: Prolonged continuous In vitro human platelet production using three-dimensional scaffolds. Exp. Hematol.37,101–110 (2009).
      Medline CASGoogle Scholar
    • 45  Colter DC, Sekiya I, Prockop DJ: Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc. Natl Acad. Sci. USA98,7841–7845 (2001).▪ One of the first papers to describe mesenchymal stem cells (MSCs).
      Medline CASGoogle Scholar
    • 46  Jiang Y, Jahagirdar BN, Reinhardt RL et al.: Pluripotency of mesenchymal stem cells derived from adult marrow. Nature418,41–49 (2002).
      Medline CASGoogle Scholar
    • 47  Reyes M, Verfaillie CM: Characterization of multipotent adult progenitor cells, a subpopulation of mesenchymal stem cells. Ann. NY Acad. Sci.938,231–233; discussion 233–235 (2001).
      Medline CASGoogle Scholar
    • 48  Beltrami AP, Cesselli D, Bergamin N et al.: Multipotent cells can be generated In vitro from several adult human organs (heart, liver, and bone marrow). Blood110,3438–3446 (2007).
      Medline CASGoogle Scholar
    • 49  D’Ippolito G, Howard GA, Roos BA, Schiller PC: Isolation and characterization of marrow-isolated adult multilineage inducible (MIAMI) cells. Exp. Hematol.34,1608–1610 (2006).
      MedlineGoogle Scholar
    • 50  D’Ippolito G, Diabira S, Howard GA et al.: Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J. Cell Sci.117,2971–2981 (2004).
      MedlineGoogle Scholar
    • 51  Kucia M, Reca R, Campbell FR et al.: A population of very small embryonic-like (VSEL) CXCR4+SSEA-1+Oct-4+ stem cells identified in adult bone marrow. Leukemia20,857–869 (2006).
      Medline CASGoogle Scholar
    • 52  Kucia M, Wysoczynski M, Ratajczak J, Ratajczak MZ: Identification of very small embryonic like (VSEL) stem cells in bone marrow. Cell Tissue Res.331,125–134 (2008).
      Medline CASGoogle Scholar
    • 53  Ratajczak MZ, Zuba-Surma EK, Wysoczynski M et al.: Hunt for pluripotent stem cell – regenerative medicine search for almighty cell. J. Autoimmun.30,151–162 (2008).
      MedlineGoogle Scholar
    • 54  Caplan AI: Why are MSCs therapeutic? New data: new insight. J. Pathol.217,318–324 (2009).▪ Excellent review of the use of MSCs as a stem cell therapy.
      Medline CASGoogle Scholar
    • 55  Brooke G, Cook M, Blair C et al.: Therapeutic applications of mesenchymal stromal cells. Semin. Cell Dev. Biol.18,846–858 (2007).
      Medline CASGoogle Scholar
    • 56  Greco SJ, Rameshwar P: Microenvironmental considerations in the application of human mesenchymal stem cells in regenerative therapies. Biologics2,699–705 (2008).
      Medline CASGoogle Scholar
    • 57  Sensebe L, Krampera M, Schrezenmeier H, Bourin P, Giordano R: Mesenchymal stem cells for clinical application. Vox Sang.98,93–107 (2010).
      Medline CASGoogle Scholar
    • 58  Sensebe L, Bourin P: Mesenchymal stem cells for therapeutic purposes. Transplantation87,S49–53 (2009).
      MedlineGoogle Scholar
    • 59  Bernardo ME, Locatelli F, Fibbe WE: Mesenchymal stromal cells. Ann. NY Acad. Sci.1176,101–117 (2009).
      Medline CASGoogle Scholar
    • 60  Rubio D, Garcia-Castro J, Martin MC et al.: Spontaneous human adult stem cell transformation. Cancer Res.65,3035–3039 (2005).
      Medline CASGoogle Scholar
    • 61  Izadpanah R, Kaushal D, Kriedt C et al.: Long-term In vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res.68,4229–4238 (2008).▪▪ Critical paper describing problems with long-term expansion of MSCs.
      Medline CASGoogle Scholar
    • 62  Rosenbaum AJ, Grande DA, Dines JS: The use of mesenchymal stem cells in tissue engineering: a global assessment. Organogenesis4,23–27 (2008).
      MedlineGoogle Scholar
    • 63  Schneider RK, Puellen A, Kramann R et al.: The osteogenic differentiation of adult bone marrow and perinatal umbilical mesenchymal stem cells and matrix remodelling in three-dimensional collagen scaffolds. Biomaterials31(3), 467–480 (2009).
      MedlineGoogle Scholar
    • 64  Taichman RS, Emerson SG: The role of osteoblasts in the hematopoietic microenvironment. Stem Cells16,7–15 (1998).▪ Important paper highlighting the role of osteoblasts in hematopoiesis.
      Medline CASGoogle Scholar
    • 65  Anselme K, Broux O, Noel B et al.: In vitro control of human bone marrow stromal cells for bone tissue engineering. Tissue Eng.8,941–953 (2002).
      Medline CASGoogle Scholar
    • 66  Palacho B, Nakamura Y, Zhang J et al.: Multipotent adult progenitor cell transplantation increases vascularity and improves left ventricular function after myocardial infarction. J. Tissue Eng. Regen. Med.1,51–59 (2007).
      MedlineGoogle Scholar
    • 67  Herdrich BJ, Lind RC, Liechty KW: Multipotent adult progenitor cells: their role in wound healing and the treatment of dermal wounds. Cytotherapy10(6),543–550 (2008).
      Medline CASGoogle Scholar
    • 68  Ratajczak MZ, Zuba-Surma EK, Shin DM et al.: Very small embryonic-like (VSEL) stem cells in adult organs and their potential role in rejuvenation of tissues and longevity. Exp. Gerontology43,1009–1017 (2008).
      Medline CASGoogle Scholar
    • 69  Zuba-Surma EK, Kucia M, Dawn B et al.: Bone marrow-derived pluripotent very small embryonic-like stem cells (VSELs) are mobilized after acute myocardial infarction. J. Mol. Cell. Cardiol.44,865–873 (2008).
      Medline CASGoogle Scholar
    • 70  May JE, Xu J, Morse HR, Avent ND, Donaldson C: Toxicity testing: the search for an In vitro alternative to animal testing. Br. J. Biomed. Sci.66,160–165 (2009).
      Medline CASGoogle Scholar
    • 101  Bringing Stem Cells to War: Meet the Blood Pharmers www.popularmechanics.com/science/health_medicine/4296060.html (Accessed 10 January 2010)
      Google Scholar
    • 102  Commission, Directive of the European Parliament of the Council (on the protection of animals used for scientific purposes) http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2008:0543:FIN:EN:PDF (Accessed 24 October 2009)
      Google Scholar
    • 103  Stem-Cell-Companies www.stem-cell-companies.com
      Google Scholar